Phase II study of OSI-774 in patients with metastatic colorectal cancer

被引：0
|
作者：
Townsley, C
Major, P
Siu, LL
Dancey, J
Vincent, M
Pond, G
MacLean, M
Moore, MJ
Oza, AM
机构：
[1] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[2] Hamilton Reg Canc Ctr, Dept Med Oncol, Hamilton, ON L8V 1C3, Canada
[3] Natl Canc Inst, Div Canc Treatment Diagnosis Ctr, Rockville, MD USA
[4] London Reg Canc Ctr, Dept Med Oncol, London, England
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
179
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [31] A phase II study of oral enzastaurin HCI in patients with metastatic colorectal cancer
    Glimelius, B.
    Lahn, M.
    Gawande, S.
    Musib, L.
    Liu, Y.
    Spindler, K. L.
    Qvortrup, C.
    Pfeiffer, P.
    Jakobsen, A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 65 - 65
  • [32] A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin
    M. Ranson
    H. Shaw
    J. Wolf
    M. Hamilton
    S. McCarthy
    E. Dean
    A. Reid
    I. Judson
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 53 - 58
  • [33] Efficacy and updated tolerability of OSI-774 (Tarceva) in patients with locally advanced or metastatic biliary (BILI) carcinoma: A multi-center phase 2 consortium (P2C) study.
    Philip, PA
    Mahoney, MR
    Thomas, JP
    Pitot, HC
    Donehower, R
    Kim, GP
    Picus, J
    Fitch, TR
    Geyer, SM
    Erlichman, C
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6097S - 6097S
  • [34] Phase II trial of edatrexate in patients with metastatic colorectal cancer
    Clamon, GH
    Riggs, CE
    Dreicer, R
    Hohl, RJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (04) : 359 - 361
  • [35] Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging
    Beeram, M
    Rowinsky, EK
    Weiss, GR
    Syed, S
    Mita, A
    Patnaik, A
    Mita, M
    Goldston, M
    De Bono, JS
    Tolcher, AW
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 207S - 207S
  • [36] A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin
    Ranson, M.
    Shaw, H.
    Wolf, J.
    Hamilton, M.
    McCarthy, S.
    Dean, E.
    Reid, A.
    Judson, I.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 53 - 58
  • [37] Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC).
    Dickler, M
    Rugo, H
    Caravelli, J
    Brogi, E
    Sachs, D
    Panageas, K
    Flores, S
    Moasser, M
    Norton, L
    Hudis, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 127S - 127S
  • [38] Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer
    Zang, D. Y.
    Lee, B. H.
    Park, H. -C.
    Song, H. H.
    Kim, H. J.
    Jung, J. Y.
    Kim, J. H.
    Kim, H. Y.
    Kwon, J. H.
    Hwang, S. W.
    Park, S. R.
    Park, C. H.
    Kim, K. O.
    Kim, M. -J.
    Jang, K. M.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 892 - 896
  • [39] A Phase II Study of Rebeccamycin Analog NSC 655649 in Patients with Metastatic Colorectal Cancer
    Sanjay Goel
    Scott Wadler
    Anthony Hoffman
    Fabio Volterra
    Cheryl Baker
    Elliot Nazario
    Percy Ivy
    Alyson Silverman
    Sridhar Mani
    Investigational New Drugs, 2003, 21 : 103 - 107
  • [40] Phase II study of oxaliplatin in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines
    Boku, Narikazu
    Ohtsu, Atsushi
    Hyodo, Ichinosuke
    Shirao, Kuniaki
    Miyata, Yoshinori
    Nakagawa, Kazuhiko
    Tamura, Takao
    Hatake, Kiyohiko
    Tanigawara, Yusuke
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (06) : 440 - 445
12345